tirzepatide gi side effects Comparative safety and of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management Weighing up the Risks: GI

Several studies have concluded that liraglutide (Saxenda) results in an average of 9 to 13 pounds of weight loss over 56 weeks

Once-weekly injectable formulations such as semaglutide and dulaglutide can be administered at any time of day, provided consistency is maintained

It costs about $450-500 per month in Australia with no PBS subsidy

Research links higher protein intake with decreased loss of muscle mass, a 32% lower risk of frailty with a 20% increase in protein intake, improved mobility, and decreased fracture risk

1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver condition worldwide, affecting approximately one-third to nearly 40% of the adult population globally, with projections indicating an increase to over 55% by 2040 ( (THR-) agonist, received approval from the FDA in 2024 for the treatment of adult patients with F2-F3 MASH ( Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained considerable attention in recent years as promising therapeutic agents for MASLD, particularly owing to their well-established efficacy in treating type 2 diabetes mellitus (T2DM) and obesity, conditions closely implicated to MASLD pathogenesis ( This review aims to systematically summarize the mechanistic insights and clinical advances of GLP-1with dual or triple receptor agonists in MASLD treatment, thereby promoting a more profound comprehension and facilitating their application in clinical practice (Figure 1)